In addition, we were able to assess the CYP21A2 genotype separately (null, I2 splice, I172N, P30L, and NC CAH), as well as outcomes before and after the introduction of the national neonatal screening in 1986. This evidence concerns the gene CYP21A2 and congenital adrenal hyperplasia.